Stryker (SYK) Competitors

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.7%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cardinal Health pays out 26.6% of its earnings in the form of a dividend. Stryker pays out 37.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cardinal Health had 4 more articles in the media than Stryker. MarketBeat recorded 32 mentions for Cardinal Health and 28 mentions for Stryker. Stryker's average media sentiment score of 1.17 beat Cardinal Health's score of 0.70 indicating that Stryker is being referred to more favorably in the news media.

Cardinal Health currently has a consensus target price of $279.44, suggesting a potential upside of 0.53%. Stryker has a consensus target price of $342.19, suggesting a potential upside of 9.62%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Cardinal Health.

Cardinal Health has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by insiders. Comparatively, 4.6% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Stryker has a net margin of 13.78% compared to Cardinal Health's net margin of 0.71%. Stryker's return on equity of 23.74% beat Cardinal Health's return on equity.

Stryker has lower revenue, but higher earnings than Cardinal Health. Stryker is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

In the previous week, Stryker had 16 more articles in the media than Cencora. MarketBeat recorded 28 mentions for Stryker and 12 mentions for Cencora. Stryker's average media sentiment score of 1.17 beat Cencora's score of 0.83 indicating that Stryker is being referred to more favorably in the news media.

Cencora presently has a consensus target price of $368.14, indicating a potential upside of 5.39%. Stryker has a consensus target price of $342.19, indicating a potential upside of 9.62%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Cencora.

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cencora pays out 13.4% of its earnings in the form of a dividend. Stryker pays out 37.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has increased its dividend for 15 consecutive years and Stryker has increased its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Cencora has higher revenue and earnings than Stryker. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a net margin of 13.78% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat Stryker's return on equity.

Cencora has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

97.5% of Cencora shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.4% of Cencora shares are held by company insiders. Comparatively, 4.6% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Stryker currently has a consensus target price of $342.19, suggesting a potential upside of 9.62%. DaVita has a consensus target price of $235.86, suggesting a potential upside of 35.40%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than Stryker.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 1.9% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, DaVita has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Stryker had 14 more articles in the media than DaVita. MarketBeat recorded 28 mentions for Stryker and 14 mentions for DaVita. Stryker's average media sentiment score of 1.17 beat DaVita's score of 0.62 indicating that Stryker is being referred to more favorably in the media.

Stryker has a net margin of 13.78% compared to DaVita's net margin of 6.49%. Stryker's return on equity of 23.74% beat DaVita's return on equity.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker currently has a consensus price target of $342.19, suggesting a potential upside of 9.62%. Medtronic has a consensus price target of $102.88, suggesting a potential upside of 1.90%. Given Stryker's stronger consensus rating and higher probable upside, equities research analysts plainly believe Stryker is more favorable than Medtronic.

Medtronic has a net margin of 13.93% compared to Stryker's net margin of 13.78%. Stryker's return on equity of 23.74% beat Medtronic's return on equity.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 2.9%. Stryker pays out 37.5% of its earnings in the form of a dividend. Medtronic pays out 70.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medtronic had 2 more articles in the media than Stryker. MarketBeat recorded 30 mentions for Medtronic and 28 mentions for Stryker. Stryker's average media sentiment score of 1.17 beat Medtronic's score of 0.98 indicating that Stryker is being referred to more favorably in the media.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.